Newsfiscal.ai
SCYNEXIS Announces Phase 1 Results and $214 Million BARDA Contract for SCY-247
· Published
Article summary
SCYNEXIS reported positive Phase 1 trial results for its intravenous antifungal candidate SCY-247 and secured up to $214 million in non-dilutive funding from BARDA to support its development.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…